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Abstract:  33 
Infection with oncogenic human papillomavirus (HPV) genotypes is necessary for the 34 
development of cervical cancer. Testing for HPV DNA from liquid based cervical 35 
samples can be used as an adjunct to traditional cytological screening. In addition 36 
there are ongoing viral load, genotyping and prevalence studies. Therefore, a sensitive 37 
DNA extraction method is needed to maximise the efficiency of HPV DNA detection. 38 
The XytXtract Tissue kit is a DNA extraction kit that is rapid and so could be useful 39 
for HPV testing, particularly in screening protocols. This study was undertaken to 40 
determine the suitability of this method for HPV detection. DNA extraction from 41 
HeLa and Caski cell lines containing HPV 18 and 16 respectively together with DNA 42 
from five liquid based cervical samples were used in a HPV PCR assay. DNA was 43 
also extracted using the QIAamp DNA mini kit (Qiagen, Hilden, Germany) as a 44 
comparison. DNA extracts were serially diluted and assayed. HPV DNA was 45 
successfully detected in cell lines and cervical samples using the XytXtract Tissue kit. 46 
In addition, the XytXtract method was found to be more sensitive than the QIAmp 47 
method as determined by a dilution series of the extracted DNA.  While the XytXtract 48 
method is a closed, the QIAamp method uses a spin column with possible loss of 49 
DNA through DNA binding competition of the matrix, which could impact on the 50 
final extraction efficiency. The XytXtract is a cheap, rapid and efficient method for 51 
extracting HPV DNA from both cell lines and liquid based cervical samples.  52 
 53 
Introduction 54 
Human papillomavirus (HPV) infection is necessary for the development of cervical 55 
cancer, which is the most prevalent cancer in women worldwide [zur Hausen et al., 56 
1981; Walboomers et al., 1999; Munoz et al., 2003]. It is recognised that the 57 
Papanicolaou screening programmes are expensive with significant limitations 58 
[Cuzick, 2002; Goldie et al., 2006]. Therefore, it has been proposed that direct testing 59 
for HPV be used in screening for cervical cancer particularly in developing countries [ 60 
Cuzick, 2002; Ronco and Segnan, 2007; Cuzick et al., 2008; Cox, 2009; Naucler et 61 
al., 2009; Darlin et al., 2013]. In addition, urine, self sampling and biopsy samples 62 
have also been investigated for their utility in HPV detection  [Carcopino et al., 2012; 63 
Darlin et al., 2013; Tanzi et al., 2013].  64 
Since HPV is quite difficult to culture [Taichman et al., 1984], DNA technologies 65 




variety of different methods have been used,  however most are based upon the 67 
Polymerase Chain Reaction (PCR) [Brestovac et al., 2005a; Klug et al., 2008; Didelot 68 
et al., 2011]. Applications are not restricted to detection of HPV, as tests for genotype 69 
determination, viral load and prevalence studies all can assist in the understanding of 70 
the relationship between HPV and cervical cancer [Brestovac et al., 2005b; 71 
Wahlström et al., 2007; Stevens et al., 2009; Broccolo et al., 2013]. Since the study of 72 
HPV has been almost performed exclusively by DNA technologies, the extraction of 73 
DNA from samples is a critical step. The availability of low cost, efficient and rapid 74 
methods being particularly useful for HPV testing in screening protocols [Dunn et al., 75 
2007]. 76 
The object of this present study was to determine the suitability of an alkaline-heat 77 
based protein degradation method [Rudbeck and Dissing, 1998; Shi et al., 2004; 78 
Chomczynski and Rymaszewski, 2006], the direct XytXtract tissue kit (Xytogen, 79 
Perth, Australia, http://xytogen.com) for extracting HPV DNA from cytology samples 80 
and cervical cancer cell lines. This method was compared to the widely used column 81 
based QIAamp DNA mini kit. To test the efficiency of the DNA extraction method, 82 
extracted DNA was diluted serially and tested by PCR. The PGMY09/11 primer set 83 
developed for a PCR test of mucosal HPV consists of a pool of primers which amplify 84 
a 450 bp region of the L1 gene within the HPV genome [Gravitt et al., 2000] and this 85 
method was selected since it is used widely. Dilution end points using this PCR were 86 
used to compare DNA extraction methods. 87 
 88 
Materials and Methods 89 
 90 
Cell lines and Samples 91 
Two cervical cancer cell lines were used: HeLa cells containing approximately 50 92 
copies of HPV 18 per cell and CaSki cells containing approximately 500 copies of 93 
HPV type 16 per cell [Yee et al., 1985; Guerin-Reverchon et al., 1989]. HeLa cells 94 
were suspended in phosphate buffered saline (PBS) at a cell concentration of 2.0 x 10
6
 95 
per mL while Caski cells were similarly suspended at 3.2 x 10
6
 per mL. This 96 
represents 1.0 x 10
6
 cells with 5.0 x 10
7
 copies of HPV 18 in a 500 µl aliquot of HeLa 97 
cells, and 1.6 x 10
6
 cells with 8.0 x 10
8
 copies of HPV 16 in a 500 µl aliquot of Caski 98 





Five high-grade cervical intraepithelial lesion (HSIL) samples in ThinPrep (Cytyc, 101 
Boxborough, MA, USA) medium were also tested. The cells suspended in the 102 
ThinPrep medium were mixed by inversion and a 500 µl aliquot was taken and used 103 
for DNA extraction. 104 
 105 
DNA Extraction 106 
DNA extraction was performed with minor modifications of the manufacturer’s 107 
protocols.  108 
For XytXtract, the 500 µl sample aliquots were centrifuged at 16,000 x g for 5 109 
minutes and supernatant discarded. The pellets was resuspended in 500 µl of PBS and 110 
centrifuged at 16,000 x g for 5 minutes and supernatant again removed. The pellets 111 
were resuspended in 1 mL of PCR grade water, centrifuged at 16,000 x g for 5 112 
minutes and supernatant removed. Solution 1A (32 μl) and solution 1B (8 μl) were 113 
added to the remaining cell pellets, mixed by vortexing and incubated at 95
o
C for 15 114 
minutes. Following incubation, 10 µl of solution 2 was added, mixed by vortexing 115 
and centrifuged at 16,000 x g for 5 minutes. The supernatant containing the DNA was 116 
removed, transferred to a sterile microfuge tube and stored at -20
o
C until required. 117 
For the QIAamp DNA mini kit, 500 µl aliquots were centrifuged at 16,000 x g for 5 118 
minutes, the supernatant discarded and cells resuspended in 200 µl of PBS. Proteinase 119 
K (20 μl) and Buffer AL (200 μl) were added and incubated at 56
o
C for 10 minutes. 120 
Absolute ethanol (200 μl) was added and the mixture applied to the QIAamp spin 121 
columns. These were centrifuged at 6,000 x g for 1 minute with waste tube discarded. 122 
The column was washed with 500 µl of buffer AW1 and again with 500 µl of AW2. 123 
The purified DNA was eluted from the spin column with 200 µl of buffer AE into a 124 
clean sterile microfuge tube and stored at -20
o
C until required. 125 
 126 
Polymerase Chain Reaction 127 
A tenfold dilution series of each of the DNA extracts from the cell lines and ThinPrep 128 
samples were performed, and the presence of HPV was detected by PCR using the 129 
PGMY09/11 primer set which amplifies a 450 bp region of the HPV L1 gene. The 130 
amplification mix was composed of 0.2 µM of each primer, 10x PCR buffer 131 
(Invitrogen, Carlsbad, CA), 2.5 mM MgCl2, 0.2 mM dNTPs, 0.5 U of Platinum Taq 132 
DNA polymerase (Invitrogen, Carlsbad, CA) and 8 µl of DNA template in a total 133 






C for 10 minutes, followed by 45 cycles of denaturation at 94
o
C for 1 135 
minute, annealing at 55
o
C for 1 minute and extension at 72
o
C for 1 minute, with a 136 
final extension step of 72
o
C for 7 minutes. Products were electrophoresed in a 2% 137 
agarose gel containing 1x TAE buffer precast with SYBR safe (Invitrogen, Carlsbad, 138 
CA) and photographed using a UV transilluminator. 139 
 140 
Results 141 
The cell lines and all ThinPrep samples extracted using the XytXtract method 142 
amplified a correct sized HPV L1 product from the PCR. However, one ThinPrep 143 
sample (sample 3) extracted using the QIAamp method failed to show an 144 
amplification product. However, a correct sized PCR fragment was present from the 145 
XytXtract extracted DNA for this same sample.   146 
An end point dilution of Hela cells, showed that in the XytXtract extracted DNA, a 147 
product could be detected at a 10
-4
 dilution, representing approximately 5 x 10
3
 copies 148 
of the HPV 18 genome. The corresponding end point dilution using QIAamp 149 
extracted DNA was 10
-2
 representing approximately 5 x 10
5
 copies of the HPV 18 150 
genome. The end point dilution for the XytXtract from Caski cells was 10
-5
 151 
representing approximately 8 x 10
3
 copies of the HPV 16 genome. The corresponding 152 
end point for the QIAamp extracted DNA was 10
-2
 representing approximately 8 x 153 
10
6
 copies of the HPV 16 genome. The XytXtract extraction method consistently 154 
resulted in a 2 to 3 log10 greater analytical sensitivity for HPV 18 and 16 genomes 155 
respectively (Table 1).  156 
The PCR results from the ThinPrep samples were expressed in dilutions since HPV 157 
copy number per cell in these samples is not known. XytXtract extraction of DNA 158 
resulted in greater analytical sensitivity for the detection of HPV than the 159 
corresponding QIAamp method for all but one sample (Table 2). Figure 1 shows the 160 
gel comparison of the end points for sample 5, which clearly shows that the sample 161 
extracted by the XytXtract method resulted in a 4 log10 greater analytical sensitivity 162 
than the QIAamp method. Further to this, the XytXtract extracted DNA from sample 163 
3 amplified a PCR product in the neat (undiluted) extract but no product was observed 164 








It has been proposed that HPV testing could be used in cervical cancer screening 170 
programmes [Cuzick, 2002; Goldie et al., 2006; Ronco and Segnan, 2007; Cuzick et 171 
al., 2008; Cox, 2009; Naucler et al., 2009; Darlin et al., 2013]. Furthermore, almost all 172 
reports in relation to HPV and cervical cancer have been DNA based, including 173 
detection, viral load, genotype determination and prevalence studies [Walboomers et 174 
al., 1999; Brestovac et al., 2005a; Brestovac et al., 2005b; Klug et al., 2008; Stevens 175 
et al., 2009; Carcopino et al., 2012; Broccolo et al., 2013]. HPV testing has a very 176 
strong negative predictive value for cervical cancer and confidence in the negative 177 
result is reliant upon the analytical sensitivity. Thus a rapid and efficient DNA 178 
extraction method would be important in HPV testing in screening protocols. The 179 
XytXtract DNA extraction method is a very rapid technique with results that are at 180 
least comparable if not greater in analytical sensitivity for testing HPV by PCR, than 181 
extraction using the QIAamp method. The analysis of DNA extracted from the cells 182 
lines showed that XytXtract method was 2 to 3 log10 more sensitive in detecting HPV 183 
18 and 16 respectively using the PGMY09/11 PCR system. All XytXtract extracted 184 
ThinPrep cytology samples showed greater or equal analytical sensitivity for the 185 
detection of HPV DNA. This greater analytical sensitivity would not only be 186 
important in screening protocols but also in studies on viral load, genotype 187 
determinations and population based distributions. In particular, ThinPrep sample 188 
number 3 did not amplify a PCR product for DNA extracted using the QIAamp 189 
method and so would be reported as negative for the presence of HPV. In contrast, the 190 
DNA from the XytXtract method amplified a product in the undiluted fraction of 191 
sample 3 and so the presence of HPV was determined.  192 
Although final volumes of extracted DNA differ between methods (50μl for 193 
XytXtract and 200μl for QIAamp), and some concentration effect could be inferred 194 
with the XytXtract method, this does not sufficiently explain the large log10 195 
differences in analytical sensitivity observed. The QIAamp system relies upon a spin 196 
column for which DNA is captured onto a binding matrix and it is conceivable that 197 
competitive binding of HPV and human DNA could result in loss of HPV DNA. In 198 
contrast, the XytXtract method is a closed system and therefore has no competitive 199 
binding to a matrix, resulting in no loss of DNA in the final extracted fluid. In 200 
addition, the XytXtract method uses an alkaline-heat protein degradation system to 201 




and Rymaszewski, 2006]. It is these factors that probably resulted in the difference in 203 
analytical sensitivity of the two DNA extraction methods. 204 
 205 
Conclusion 206 
HPV detection, viral load and genotyping are performed primarily by DNA 207 
techniques and so the DNA extraction method is critical. The XytXtract DNA 208 
extraction method is a closed alkaline-heat protein degradation system that is both 209 
rapid and efficient and so very suitable for extracting DNA from cell lines and liquid 210 
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